Dean Lim
About
Dean Lim is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery.
According to data from OpenAlex, Dean Lim has authored 72 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 39 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 18 papers in Surgery. Recurrent topics in Dean Lim's work include Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Dean Lim is often cited by papers focused on Colorectal Cancer Treatments and Studies (17 papers), Cancer Treatment and Pharmacology (14 papers) and Lung Cancer Treatments and Mutations (11 papers). Dean Lim collaborates with scholars based in United States, Taiwan and Singapore. Dean Lim's co-authors include Robert J. Morgan, Marwan Fakih, Yun Yen, Joseph Chao, Jaideep Sandhu, Paul Frankel, Lucille Leong, Mark E. Davis, Jonathan E. Zuckerman and Antoni Ribas and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Dean Lim
69 papers receiving 2.1k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Dean Lim United States | 24 | 971 | 706 | 461 | 417 | 330 | 72 | 2.1k | ||
| Susana M. Campos United States | 28 | 1.6k 1.7× | 859 1.2× | 319 0.7× | 449 1.1× | 346 1.0× | 101 | 3.3k | ||
| Andrew R. Clamp United Kingdom | 24 | 739 0.8× | 734 1.0× | 222 0.5× | 276 0.7× | 227 0.7× | 116 | 2.0k | ||
| Carolyn Krasner United States | 26 | 1.0k 1.1× | 627 0.9× | 463 1.0× | 528 1.3× | 302 0.9× | 107 | 2.5k | ||
| Ralph J. Hauke United States | 25 | 1.2k 1.2× | 983 1.4× | 541 1.2× | 927 2.2× | 418 1.3× | 101 | 2.7k | ||
| P. Vasey United Kingdom | 33 | 1.7k 1.7× | 1.3k 1.8× | 983 2.1× | 655 1.6× | 459 1.4× | 97 | 3.8k | ||
| George P. Stathopoulos Greece | 28 | 1.4k 1.4× | 689 1.0× | 235 0.5× | 457 1.1× | 395 1.2× | 105 | 2.6k | ||
| David E. Parkin United Kingdom | 29 | 1.1k 1.1× | 451 0.6× | 1.1k 2.3× | 335 0.8× | 212 0.6× | 93 | 4.3k | ||
| Jeanny B. Aragon‐Ching United States | 27 | 1.4k 1.4× | 692 1.0× | 600 1.3× | 1.2k 2.9× | 455 1.4× | 141 | 2.9k | ||
| Taito Esaki Japan | 29 | 2.1k 2.2× | 743 1.1× | 581 1.3× | 1.4k 3.5× | 235 0.7× | 184 | 3.3k | ||
| Sun Young Min South Korea | 24 | 430 0.4× | 489 0.7× | 403 0.9× | 194 0.5× | 539 1.6× | 60 | 1.7k |
Countries citing papers authored by Dean Lim
Since
Specialization
Citations
This map shows the geographic impact of Dean Lim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dean Lim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dean Lim more than expected).
Fields of papers citing papers by Dean Lim
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Dean Lim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dean Lim. The network helps show where Dean Lim may publish in the future.
Co-authorship network of co-authors of Dean Lim
This figure shows the co-authorship network connecting the top 25 collaborators of Dean Lim. A scholar is included among the top collaborators of Dean Lim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dean Lim. Dean Lim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Soto‐Pérez‐de‐Celis, Enrique, William Dale, Vani Katheria, et al.. (2024). Outcome prioritization and preferences among older adults with cancer starting chemotherapy in a randomized clinical trial. Cancer. 130(17). 3000–3010.
2.
Fakih, Marwan, et al.. (2023). Regorafenib, Ipilimumab, and Nivolumab for Patients With Microsatellite Stable Colorectal Cancer and Disease Progression With Prior Chemotherapy. JAMA Oncology. 9(5). 627–627.
3.
Raoof, Mustafa, Kevin M. Sullivan, Paul Frankel, et al.. (2022). Multicenter dose-escalation Phase I trial of mitomycin C pressurized intraperitoneal aerosolized chemotherapy in combination with systemic chemotherapy for appendiceal and colorectal peritoneal metastases: rationale and design. SHILAP Revista de lepidopterología. 7(4). 169–177.
4.
Raoof, Mustafa, Gautam Malhotra, Michael P. O’Leary, et al.. (2021). PIPAC for the Treatment of Gynecologic and Gastrointestinal Peritoneal Metastases: Technical and Logistic Considerations of a Phase 1 Trial. Annals of Surgical Oncology. 29(1). 175–185.
5.
Kochanny, Sara, Francis P. Worden, Douglas R. Adkins, et al.. (2020). A randomized phase 2 network trial of tivantinib plus cetuximab versus cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Cancer. 126(10). 2146–2152.
6.
Akhavan, David, Paul J. Yazaki, Dave Yamauchi, et al.. (2020). Phase I Study of Yttrium-90 Radiolabeled M5A Anti-Carcinoembryonic Antigen Humanized Antibody in Patients with Advanced Carcinoembryonic Antigen Producing Malignancies. Cancer Biotherapy and Radiopharmaceuticals. 35(1). 10–15.
7.
Cristea, Mihaela, Paul Frankel, Timothy W. Synold, et al.. (2019). A phase I trial of intraperitoneal nab-paclitaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity. Cancer Chemotherapy and Pharmacology. 83(3). 589–598.
8.
Luu, Thehang, Paul Frankel, Jan H. Beumer, et al.. (2019). Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial. Cancer Chemotherapy and Pharmacology. 84(6). 1201–1208.
9.
Schrock, Alexa B., Ching Ouyang, Jaideep Sandhu, et al.. (2019). Tumor mutational burden is predictive of response to immune checkpoint inhibitors in MSI-high metastatic colorectal cancer. Annals of Oncology. 30(7). 1096–1103.
10.
Chao, Joseph, James Lin, Paul Frankel, et al.. (2017). Pilot trial of CRLX101 in patients with advanced, chemotherapy-refractory gastroesophageal cancer. Journal of Gastrointestinal Oncology. 8(6). 962–969.
11.
Hurria, Arti, Chie Akiba, Jérôme H. Kim, et al.. (2016). Reliability, Validity, and Feasibility of a Computer-Based Geriatric Assessment for Older Adults With Cancer. Journal of Oncology Practice. 12(12). e1025–e1034.
12.
Wong, Stuart J., Theodore Karrison, D. Neil Hayes, et al.. (2015). Phase II trial of dasatinib for recurrent or metastatic c-KIT expressing adenoid cystic carcinoma and for nonadenoid cystic malignant salivary tumors. Annals of Oncology. 27(2). 318–323.
13.
Hardwick, Nicola, Mary Carroll, Teodora Kaltcheva, et al.. (2014). p53MVA Therapy in Patients with Refractory Gastrointestinal Malignancies Elevates p53-Specific CD8+ T-cell Responses. Clinical Cancer Research. 20(17). 4459–4470.
14.
Frankel, Paul, Timothy W. Synold, Joanne Mortimer, et al.. (2014). Phase I study of the halichondrin B analogue eribulin mesylate in combination with cisplatin in advanced solid tumors. British Journal of Cancer. 111(12). 2268–2274.
15.
Yong, Wei Peng, Boon Cher Goh, Ross A. Soo, et al.. (2011). Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases, SB939, in patients with refractory solid malignancies. Annals of Oncology. 22(11). 2516–2522.
16.
Morgan, Robert J., Timothy W. Synold, Adam N. Mamelak, et al.. (2010). Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors. Cancer Chemotherapy and Pharmacology. 66(5). 927–933.
17.
Kernstine, Kemp H., Stephen Shibata, Dean Lim, et al.. (2007). Initial Experience With Helical Tomotherapy for Locally Advanced Esophageal Cancer by Concomitant Boost Strategy. International Journal of Radiation Oncology*Biology*Physics. 69(3). S308–S308.
18.
Shibata, Stephen, Warren Chow, Paul Frankel, et al.. (2006). A phase I study of oxaliplatin in combination with gemcitabine: correlation of clinical outcome with gene expression. Cancer Chemotherapy and Pharmacology. 59(4). 549–557.
19.
Lim, Dean, Robert J. Morgan, Steven A. Akman, et al.. (2005). Phase I trial of menadiol diphosphate (vitamin K3) in advanced malignancy. Investigational New Drugs. 23(3). 235–239.
20.
Chow, Warren, Timothy W. Synold, Merry Tetef, et al.. (2004). Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. Cancer Chemotherapy and Pharmacology. 54(3). 241–248.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Susana M. Campos Breakdown of academic impact, for papers by Andrew R. Clamp Breakdown of academic impact, for papers by Carolyn Krasner Breakdown of academic impact, for papers by Ralph J. Hauke Breakdown of academic impact, for papers by P. Vasey Breakdown of academic impact, for papers by George P. Stathopoulos Breakdown of academic impact, for papers by David E. Parkin Breakdown of academic impact, for papers by Jeanny B. Aragon‐Ching Breakdown of academic impact, for papers by Taito Esaki Breakdown of academic impact, for papers by Sun Young Min